AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

Search

Prospect Capital Corp

Suletud

SektorRahandus

2.89 -0.34

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.8

Max

2.9

Põhinäitajad

By Trading Economics

Sissetulek

-140M

-140M

Müük

-108M

-93M

P/E

Sektori keskmine

14.86

25.916

Dividenditootlus

18.64

Kasumimarginaal

150.257

EBITDA

-178M

-140M

Soovitused

By TipRanks

Soovitused

Müü

12 kuu keskmine prognoos

+1.01% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

18.64%

3.70%

Järgmine tulemuste avaldamine

27. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-277M

1.5B

Eelmine avamishind

3.23

Eelmine sulgemishind

2.89

Uudiste sentiment

By Acuity

60%

40%

462 / 536 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Prospect Capital Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 21:42 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4. aug 2025, 21:21 UTC

Tulu
Suurimad hinnamuutused turgudel

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. aug 2025, 20:45 UTC

Tulu

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. aug 2025, 19:15 UTC

Suurimad hinnamuutused turgudel

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4. aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4. aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4. aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4. aug 2025, 21:30 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. aug 2025, 21:21 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4. aug 2025, 21:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss $938M >RIG

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss/Shr $1.06 >RIG

4. aug 2025, 20:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4. aug 2025, 20:15 UTC

Tulu

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. aug 2025, 20:13 UTC

Tulu

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. aug 2025, 20:09 UTC

Tulu

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4. aug 2025, 20:06 UTC

Tulu

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4. aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4. aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4. aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4. aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Prospect Capital Corp Prognoos

Hinnasiht

By TipRanks

1.01% tõus

12 kuu keskmine prognoos

Keskmine 3 USD  1.01%

Kõrge 3 USD

Madal 3 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Prospect Capital Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

1 ratings

0

Osta

0

Hoia

1

Müü

Tehniline skoor

By Trading Central

3.6 / 3.69Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

462 / 536 Pingereas Rahandus

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Prospect Capital Corp

Prospect Capital Corporation is a business development company. It specializes in middle market, mature, mezzanine finance, later stage, emerging growth, leveraged buyouts, refinancing, acquisitions, recapitalizations, turnaround, growth capital, development, capital expenditures and subordinated debt tranches of collateralized loan obligations, cash flow term loans, market place lending and bridge transactions. It also makes real estate investments particularly in multi-family residential real estate asset class. The fund makes secured debt, senior debt, senior and secured term loans, unitranche debt, first-lien and second lien, private debt, private equity, mezzanine debt, and equity investments in private and microcap public businesses. It focuses on both primary origination and secondary loans/portfolios and invests in situations like debt financings for private equity sponsors, acquisitions, dividend recapitalizations, growth financings, bridge loans, cash flow term loans, real estate financings/investments. It also focuses on investing in small-sized and medium-sized private companies rather than large public companies. The fund typically invests across all industry sectors, with a particular expertise in the energy and industrial sectors. It invests in aerospace and defense, chemicals, conglomerate services, consumer services, ecological, electronics, financial services, machinery, manufacturing, media, pharmaceuticals, retail, software, specialty minerals, textiles and leather, transportation, oil and gas production, coal production, materials, industrials, consumer discretionary, information technology, utilities, pipeline, storage, power generation and distribution, renewable and clean energy, oilfield services, healthcare, food and beverage, education, business services, and other select sectors. It prefers to invest in the United States and Canada. The fund seeks to invest between $10 million to $500 million per transaction in companies with EBITDA between $5 million and $150 million, sales value betw